Page 66 - 2021_06-Haematologica-web

M.B. Geyer et al.
Significant improvement of outcome In
adolescents and young adults (AYAs) aged 15-35 Years with acute lymphoblastic leukemia (ALL) with a pediatric derived adult ALL protocol; results Of 1529 AYAs in 2 consecutive trials of The German Multicenter Study Group For Adult ALL (GMALL). Blood. 2013;122(21):839-839.
13. Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548-1559.
14. Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2009;7(9):600-606.
15.Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consoli- dation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblas- tic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335-342.
16. Sallan SE, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983;43(11):5601-5607.
17. Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparagi- nase/pegasparaginase-associated toxicities in adults and older adolescents: recommen- dations of an expert panel. Leuk Lymphoma. 2011;52(12):2237-2253.
18. Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11(9):1780-1786.
19. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyeth- ylene glycol conjugated asparaginase for treatment of children with newly diag- nosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99(6):1986-1994.
20.Muller HJ, Loning L, Horn A, et al. Pegylated asparaginase (Oncaspar) in chil- dren with ALL: drug monitoring in reinduc- tion according to the ALL/NHL-BFM 95 protocols. Br J Haematol. 2000;110(2):379-
384.
21. Larsen EC, Devidas M, Chen S, et al.
Dexamethasone and high-dose methotrex- ate improve outcome for children and young adults with high-risk B-acute lym- phoblastic leukemia: a report from Children's Oncology Group Study AALL0232. J Clin Oncol. 2016;34(20):2380- 2388.
22. Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegy- lated asparaginase results in improved out- comes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007;109(10):4164- 4167.
23. Rubenstein JL, Gupta NK, Mannis GN, et al. How I treat CNS lymphomas. Blood. 2013;122(14):2318-2330.
24. Khan RB, Shi W, Thaler HT, et al. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol. 2002;58(2):175-178.
25. Synold TW, Relling MV, Boyett JM, et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest. 1994;94(5):1996-2001.
26. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adoles- cents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111(5):2548- 2555.
27. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblas- tic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338(23):1663- 1671.
28. Christ TN, Stock W, Knoebel RW. Incidence of asparaginase-related hepato- toxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2018;24(4): 299-308.
29. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lym- phoblastic leukaemia. Lancet Oncol.
2009;10(2):147-156.
30. Orvain C, Balsat M, Tavernier E, et al.
Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study. Blood. 2020;136(3):328-338.
31. Quist-Paulsen P, Toft N, Heyman M, et al. T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pedi- atric NOPHO ALL2008 protocol. Leukemia. 2020;34(2):347-357.
32. Luskin MR, DeAngelo DJ. T-cell acute lym- phoblastic leukemia: Current approach and future directions. Adv Cell Gene Ther. 2019;2(4):e70.
33.Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intra- venous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lym- phoblastic leukemia. Blood. 2007;109(7): 2744-2750.
34. Lanvers-Kaminsky C, Niemann A, Eveslage M, et al. Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diag- nosed acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61(1):138-145.
35. Patel B, Rai L, Buck G, et al. Minimal resid- ual disease is a significant predictor of treat- ment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol. 2010;148 (1):80-89.
36. Inotuzumab Ozogamicin and Blinatumomab in treating patients with newly diagnosed, recurrent, or refractory CD22-positive B-lineage acute lymphoblas- tic leukemia. [cited; available from: https://clinicaltrials.gov/ct2/show/NCT037 39814
37. Combination chemotherapy with or with- out blinatumomab in treating patients with newly diagnosed BCR-ABL-negative B line- age acute lymphoblastic leukemia. https://clinicaltrials.gov/ct2/show/NCT0 2003222
38.Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph- like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005-1015.
2094
haematologica | 2021; 106(8)